You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR QUZYTTIR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for QUZYTTIR

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02935699 ↗ Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria Completed JDP Therapeutics, Inc. Phase 3 2017-03-01 This is a multicenter, parallel group, randomized, double-blind, active controlled, Phase III clinical study of cetirizine injection, 10 mg/mL, compared to diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent) with acute urticaria requiring treatment.
NCT04189588 ↗ Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine Completed TerSera Therapeutics Phase 2 2020-03-25 This study is designed to compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment.
NCT04189588 ↗ Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine Completed JDP Therapeutics, Inc. Phase 2 2020-03-25 This study is designed to compare the incidence of infusion reactions to treatment with an anti-CD20 such as Rituxan® (rituximab) or Taxol® (Paclitaxel) after premedication with intravenous (IV) QUZYTTIR™ cetirizine hydrochloride (HCl) or IV diphenhydramine during first-cycle infusion or re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel. Re-treatment is defined as re-treatment with an anti-CD20 such as Rituxan® (rituximab) or Paclitaxel after 6 months or in patients with persistent infusion reactions while on maintenance or retreatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for QUZYTTIR

Condition Name

Condition Name for QUZYTTIR
Intervention Trials
Oncology Patients Receiving Chemotherapy 1
Acute Urticaria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for QUZYTTIR
Intervention Trials
Neoplasms 1
Hypersensitivity 1
Urticaria 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for QUZYTTIR

Trials by Country

Trials by Country for QUZYTTIR
Location Trials
United States 5
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for QUZYTTIR
Location Trials
Texas 2
California 1
Pennsylvania 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for QUZYTTIR

Clinical Trial Phase

Clinical Trial Phase for QUZYTTIR
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for QUZYTTIR
Clinical Trial Phase Trials
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for QUZYTTIR

Sponsor Name

Sponsor Name for QUZYTTIR
Sponsor Trials
JDP Therapeutics, Inc. 2
TerSera Therapeutics 1
TerSera Therapeutics LLC 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for QUZYTTIR
Sponsor Trials
Industry 3
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.